Ironwood Pharmaceuticals
IRWD
227 hedge funds and large institutions have $2.31B invested in Ironwood Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 84 increasing their positions, 70 reducing their positions, and 17 closing their positions.
358% more call options, than puts
Call options by funds: $13.1M | Put options by funds: $2.87M
124% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 17
20% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 70
9% more funds holding
Funds holding: 208 → 227 (+19)
1.17% more ownership
Funds ownership: 107.75% → 108.92% (+1.2%)
3% more capital invested
Capital invested by funds: $2.24B → $2.31B (+$69M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$44.6M |
| 2 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$25.9M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$24.8M |
| 4 |
BlackRock
New York
|
+$11.9M |
| 5 |
FP
Foundry Partners
Minneapolis,
Minnesota
|
+$11.5M |
Top Sellers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$46.4M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$25.8M |
| 3 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$19.1M |
| 4 |
Renaissance Technologies
New York
|
-$15.9M |
| 5 |
BM
Bridger Management
New York
|
-$13.8M |
IRWD Hedge Fund Activity: Q3 2021 in Review
227 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q3 2021, worth a combined $2.31B — up 3.1% from $2.24B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new IRWD positions and 17 closed out — a net gain of 21 holders — while 84 added to existing stakes and 70 trimmed.
The largest buyer was LSV Asset Management, adding an estimated $44.6M. The largest seller was Wellington Management Group, cutting an estimated $46.4M.
- 227 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q3 2021, up from 208 in Q2 2021.
- Funds reported $2.31B of Ironwood Pharmaceuticals stock for Q3 2021, up 3.1% quarter-over-quarter.
- 38 funds opened new Ironwood Pharmaceuticals positions in Q3 2021 and 17 closed out, a net change of +21 holders.
- The largest Ironwood Pharmaceuticals buyer in Q3 2021 was LSV Asset Management, an estimated $44.6M added.
- The largest Ironwood Pharmaceuticals seller in Q3 2021 was Wellington Management Group, an estimated $46.4M sold.
Based on aggregated 13F filings for Q3 2021.